A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This 2-part, randomized, double-blind, placebo-controlled study will assess the safety,
pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with
hepatitis C infection. Cohorts will be randomized to receive either RO5428029 in ascending
doses or placebo for up to 7 days (patients) or up to 14 days (healthy volunteers).